These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 29243123)

  • 21. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
    Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
    Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy:
    Soloff EV; Al-Hawary MM; Desser TS; Fishman EK; Minter RM; Zins M
    AJR Am J Roentgenol; 2022 Apr; 218(4):570-581. PubMed ID: 34851713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning.
    Zaky AM; Wolfgang CL; Weiss MJ; Javed AA; Fishman EK; Zaheer A
    Radiographics; 2017; 37(1):93-112. PubMed ID: 27885893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of response in neoadjuvant therapy for exocrine pancreatic cancer.
    Vitello DJ; Bentrem DJ
    J Surg Oncol; 2021 May; 123(6):1449-1459. PubMed ID: 33831249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does CT overestimate extra-pancreatic perineural invasion in patients with pancreatic ductal adenocarcinoma following neoadjuvant chemoradiation therapy?
    Noda Y; Pisuchpen N; Parakh A; Srinivas-Rao S; Kinowaki Y; Mino-Kenudson M; Kambadakone AR
    Br J Radiol; 2024 Feb; 97(1155):607-613. PubMed ID: 38305574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer.
    Tummers WS; Willmann JK; Bonsing BA; Vahrmeijer AL; Gambhir SS; Swijnenburg RJ
    Pancreas; 2018 Jul; 47(6):675-689. PubMed ID: 29894417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
    Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
    Kong Y; Xie F; Zhang Z; Wang S; Zhang Y; Di Y; Zhou Z; Jiang D; Li J; Huang Q; Wang J; Li X; Pan Z; Ni R; Guan Y
    Eur Radiol; 2023 Oct; 33(10):7077-7088. PubMed ID: 37166496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Radiological evaluation of pancreatic ductal adenocarcinoma].
    Akai H; Otomo K
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):342-6. PubMed ID: 22421758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.
    Wang ZJ; Zhang TT; An C; Ko AH; Tempero M; Collisson E; Yeh BM
    AJR Am J Roentgenol; 2020 Sep; 215(3):610-616. PubMed ID: 32755156
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
    Hong Y; Rice J; Sharma D; Martin RCG
    Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know.
    Smith DA; Somarouthu B; Ramaiya NH
    Abdom Radiol (NY); 2019 Jun; 44(6):2182-2195. PubMed ID: 30820626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
    Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
    Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical oncology and pancreatic cancer: what the radiologist needs to know.
    Fogelman DR; Varadhachary G
    Abdom Radiol (NY); 2018 Feb; 43(2):383-392. PubMed ID: 29285600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.
    Tesfaye AA; Kamgar M; Azmi A; Philip PA
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):131-148. PubMed ID: 29254387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
    Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
    Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Ferrone CR
    Dig Surg; 2016; 33(4):343-50. PubMed ID: 27216011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.
    Hu X; Xia F; Lee J; Li F; Lu X; Zhuo X; Nie G; Ling D
    Adv Sci (Weinh); 2021 Apr; 8(7):2002545. PubMed ID: 33854877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
    Trajkovic-Arsic M; Heid I; Steiger K; Gupta A; Fingerle A; Wörner C; Teichmann N; Sengkwawoh-Lueong S; Wenzel P; Beer AJ; Esposito I; Braren R; Siveke JT
    Sci Rep; 2017 Dec; 7(1):17038. PubMed ID: 29213099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.